Pioglitazone as Second-Line in Patients With Metastatic Pancreatic Cancer After Treatment With Gemcitabine
Stopped early · Early Phase 1
Conditions studied: Pancreatic Cancer
In brief
RATIONALE: Pioglitazone may slow the growth of tumor cells and may be an effective treatment for pancreatic cancer. PURPOSE: This phase I trial is studying how well pioglitazone works as second-line therapy in treating patients with metastatic pancreatic cancer that progressed after treatment with gemcitabine.
Key facts
- Study ID
- NCT00867126
- Run by
- University of Texas Southwestern Medical Center
- People needed
- 6
- Starts
- 2009-03-02
- Expected to finish
- 2012-02-01
- Last updated by the study team
- 2018-11-26
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas — Dallas, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.